Fermenta Biotech Ltd
NSE: BSE: 506414
₹336.60
(-0.80%)
Thu, 19 Mar 2026, 00:57 am
Market Cap9.99B
PE Ratio11.21
Dividend0.74
Health Technology
Biotechnology
24.5KFermenta Biotech Analysis
dividend
- Dividends per share have increased over the past 10 years.
- Dividends paid are thoroughly covered by earnings (76.6x coverage).
- Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
- Fermenta Biotech's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Fermenta Biotech's dividend is below the markets top 25% of dividend payers in India (3.08%).
health
- Fermenta Biotech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Fermenta Biotech is profitable, therefore cash runway is not a concern.
- Fermenta Biotech is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (31.4%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 1.5x debt.
- Fermenta Biotech's cash and other short term assets cover its long term commitments.
- Interest payments on debt are well covered by earnings (EBIT is 4.5x coverage).
- The level of debt compared to net worth has increased over the past 5 years (20.5% vs 69.8% today).
- Fermenta Biotech's level of debt (69.8%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Fermenta Biotech board of directors is about average.
- The tenure for the Fermenta Biotech management team is about average.
misc
- Fermenta Biotech is not covered by any analysts.
- Fermenta Biotech has significant price volatility in the past 3 months.
past
- Fermenta Biotech has delivered over 20% year on year earnings growth in the past 5 years.
- Fermenta Biotech used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Fermenta Biotech has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Fermenta Biotech has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
- Fermenta Biotech's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- Fermenta Biotech's 1-year earnings growth is negative, it can't be compared to the IN Pharmaceuticals industry average.
value
- Fermenta Biotech is good value based on earnings compared to the IN Pharmaceuticals industry average.
- Fermenta Biotech is good value based on earnings compared to the India market.
- 506414 outperformed the Market in India which returned -14.5% over the past year.
- BSE:506414 is up 23.8% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:506414 is up 23.8% outperforming the market in India which returned 8% over the past month.
- Fermenta Biotech's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Fermenta Biotech's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Fermenta Biotech is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- 506414 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800